Home > Publications database > Efficacy and Safety of Donor Lymphocyte Infusion After Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients. > print

001     307536
005     20260220120942.0
024 7 _ |a 10.1111/ejh.70112
|2 doi
024 7 _ |a pmid:41489018
|2 pmid
024 7 _ |a 0902-4441
|2 ISSN
024 7 _ |a 0036-553X
|2 ISSN
024 7 _ |a 1600-0609
|2 ISSN
037 _ _ |a DKFZ-2026-00041
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Walther, Dinah
|b 0
245 _ _ |a Efficacy and Safety of Donor Lymphocyte Infusion After Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients.
260 _ _ |a Oxford
|c 2026
|b Wiley-Blackwell
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1767623496_2785348
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a epub
520 _ _ |a This retrospective study evaluates the efficacy and safety of donor lymphocyte infusion (DLI) after allogeneic hematopoietic stem cell transplantation (HSCT) in children. We describe the long-term use of preemptive, prophylactic, and therapeutic DLI with a gradual dose increase in half-log increments. Under close monitoring, we increased the DLI dose only in patients that did not show signs of graft-versus-host disease (GVHD). In the preemptive cohort, 10 of 12 patients (83%) with minimal residual disease (MRD) positivity remained relapse-free. Among 11 patients with genetic diseases and mixed chimerism, nine (82%) responded to preemptive DLI. Six patients (100%) of the prophylactic cohort with a very high risk of relapse had a successful outcome without relapse or GVHD. Three of the five patients (60%) of the therapeutic cohort were successfully treated with DLI. We observed acute GVHD (grade I and II) in only two patients (6%). The results of our study indicate that the long-term use of DLI is a promising strategy and can effectively prevent relapse, graft rejection, and even cure relapse. The observed low rate of GVHD may be attributed to the gradual dose increase. Therefore, we consider DLI a safe and effective therapeutic option.
536 _ _ |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312)
|0 G:(DE-HGF)POF4-312
|c POF4-312
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a donor chimerism
|2 Other
650 _ 7 |a donor lymphocyte infusion
|2 Other
650 _ 7 |a graft‐versus‐host disease
|2 Other
650 _ 7 |a graft‐versus‐leukemia effect
|2 Other
650 _ 7 |a hematopoietic stem cell transplantation
|2 Other
700 1 _ |a Ernst, Jana
|b 1
700 1 _ |a Wollenhaupt, Carola
|b 2
700 1 _ |a Wittig, Susan
|b 3
700 1 _ |a Härtel, Manuela
|b 4
700 1 _ |a Brodt, Grit
|b 5
700 1 _ |a Milde, Till
|0 P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f
|b 6
|u dkfz
700 1 _ |a Gruhn, Bernd
|b 7
773 _ _ |a 10.1111/ejh.70112
|g p. ejh.70112
|0 PERI:(DE-600)2027114-1
|p nn
|t European journal of haematology
|v nn
|y 2026
|x 0902-4441
856 4 _ |y OpenAccess
|u https://inrepo02.dkfz.de/record/307536/files/European%20J%20of%20Haematology%20-%202026%20-%20Walther%20-%20Efficacy%20and%20Safety%20of%20Donor%20Lymphocyte%20Infusion%20After%20Allogeneic.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://inrepo02.dkfz.de/record/307536/files/European%20J%20of%20Haematology%20-%202026%20-%20Walther%20-%20Efficacy%20and%20Safety%20of%20Donor%20Lymphocyte%20Infusion%20After%20Allogeneic.pdf?subformat=pdfa
909 C O |o oai:inrepo02.dkfz.de:307536
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-312
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Funktionelle und strukturelle Genomforschung
|x 0
914 1 _ |y 2026
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-06
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EUR J HAEMATOL : 2022
|d 2024-12-06
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2024-12-06
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-06
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-06
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2024-12-06
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-06
920 1 _ |0 I:(DE-He78)B310-20160331
|k B310
|l KKE Pädiatrische Onkologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-He78)B310-20160331
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21